Expedition Therapeutics has raised $115.0M in a Series B round, a sizable bet on its pipeline of therapies for inflammatory and respiratory diseases. The biotech, which focuses on serious conditions in those areas, will use the capital to advance its lead programs, though specifics on the next milestones were not disclosed.
The round鈥檚 backers remain unnamed, but the size alone signals investor confidence in the company鈥檚 approach. With respiratory and inflammatory diseases representing a crowded but high-need field, Expedition鈥檚 ability to stand out will hinge on clinical execution.
